USSOCOM Awards Vricon Foreign Comparative Test Contract

Vricon to increase the resolution and accuracy of SOCOM’s 3D geospatial data McLean, Virginia, Nov. 09, 2017 (GLOBE NEWSWIRE) — The US Special Operations Command (USSOCOM) awarded Vricon a contract for a Foreign Comparative Test for commercial data, software, and testing to increase the resolution and accuracy of the Command’s 3D geospatial data.  Vricon also will work to automate workflows […]

Nasdaq Wins RiskTech100® Best Operational Risk & GRC Category

Awarded by Chartis Research, the accolade spotlights the major players in risk technology  NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq:NDAQ), one of the world’s leading Governance, Risk management and Compliance (GRC) solution providers, has won the Best Operational Risk & GRC provider at the RiskTech100® 2018 awards. Nasdaq’s four commercial offerings were considered […]

Disruptive Semiconductor Technology Leader Luxcore Signs Multi-year Colocation Deal with INAP

Luxcore selects INAP to support their ground breaking second generation LambdaRouterTM — the first full wavelength optical router. INAP chosen for its global presence in strategic markets, carrier neutrality and signature Performance IPTM service. ATLANTA, Nov. 09, 2017 (GLOBE NEWSWIRE) — Internap Corporation (NASDAQ:INAP), (“INAP” or the “Company”), a provider of high-performance internet infrastructure including […]

RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease

Top-line results are expected to be announced in mid-2018 The Phase III study evaluating RHB-104 for Crohn’s disease (MAP US study) is a randomized, double-blind, placebo-controlled study that is evaluating the safety and efficacy of RHB-104 in 331 subjects with moderately to severely active Crohn’s disease Worldwide sales of Crohn’s disease therapies exceeded $7.6 billion […]

Telix Pharmaceuticals Limited Successfully Completes $50 Million Oversubscribed Initial Public Offering

MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has successfully raised $50 million following the close of its fully underwritten Initial Public Offering (IPO). The IPO was strongly […]